Online citations, reference lists, and bibliographies.
← Back to Search

Single Hormone Receptor-Positive Breast Cancers Have Distinct Characteristics And Survival

C. Dauphine, A. Moazzez, Jasmin C. Neal, R. Chlebowski, J. Ozao-Choy
Published 2020 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Estrogen receptor (ER) and progesterone receptor (PR) status is pivotal to determining the prognosis and treatment of human epidermal growth factor 2 (HER2) receptor-negative invasive breast cancer. Frequently ER-positive (ER+) and/or PR-positive (PR+) cancers are labeled nonspecifically as “hormone receptor-positive” although only one is positive. This study aimed to evaluate and characterize the ER+PR− and ER−PR+ breast cancer phenotypes in reference to ER+PR+ cancers. A retrospective cohort study of female patients with HER2-negative (HER2−) invasive breast cancer diagnosed in 2010−2015 was performed using the National Cancer Database. Cases were grouped into ER+PR+, ER−PR+, ER+PR−, and ER−PR− phenotypes to determine differences in patient demographics, tumor characteristics, and overall survival. Of 823,969 cases, 619,050 (75.1%) were ER+PR+, 79,777 (9.7%) were ER+PR−, 7006 (0.9%) were ER−PR+, and 118,136 (14.3%) were ER−PR−. Compared with the ER+PR+ group, the ER+PR− and ER−PR+ groups were more likely to be high-grade cancer (16.0% vs. 34.2% and 80.0%, respectively; p < 0.001), to have lymphovascular invasion (17.9% vs. 19.6% and 23.0%; p < 0.001), to be node-positive (13.5% vs. 19.7% and 26.3%; p < 0.001), to be stage 4 cancer (3.6% vs. 5.9% and 6.7%; p < 0.001), to have a higher multigene assay score (mean, 16.0 vs. 27.8 and 38.1; p < 0.001), and to have a worse survival (90.6% vs. 83.8% and 78.1%; p < 0.001). Single hormone receptor-positive breast cancer subtypes (ER+PR− and ER−PR+) are more likely to have unfavorable characteristics and worse survival than the ER+PR+ subtype, with the ER−PR+ subtype having outcomes similar to those for ER−PR− cancers. The single hormone receptor-positive subtypes, representing 10% of HER2− cancers, should be considered clinically distinct from ER+PR+ disease.
This paper references
National Comprehensive Cancer Network Breast Cancer ( version 3 . 2020 ) . Invasive Breast Cancer , Systemic Adjuvant Treatment ( BINV - 4 )
L DeMaeyer
Adjuvant Chemotherapy Guided by a 21‐Gene Expression Assay in Breast Cancer
J. Sparano (2018)
Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype.
E. Rakha (2007)
Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME II): a randomised controlled trial.
I. Kunkler (2015)
Clinicopathological Characteristics and Breast Cancer–Specific Survival of Patients With Single Hormone Receptor–Positive Breast Cancer
Yunhai Li (2020)
breast cancer subtypes, and survival in the Carolina Breast Cancer Study
L A Carey (2006)
Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer
IH Kunkler (2015)
Breast Cancer Facts and Figures 2019-2020. Retrieved
Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations
AMERICAN College of Surgeons.
L. Post (1947)
Estrogen receptor negative/progesterone receptor positive breast cancer is not a reproducible subtype
M. Hefti (2013)
Relevance of progesterone receptor immunohistochemical staining to Oncotype DX recurrence score.
Lubna N Chaudhary (2016)
The influence of body composition and hormone replacement therapy (HRT) on progesterone receptor (PR) expression in postmenopausal women with an oestrogen receptor (ER)-positive breast cancer
T. Mieghem (2006)
Grade/differentiation \0
Annual Report to the Nation on the Status of Cancer, 1975-2011, Featuring Incidence of Breast Cancer Subtypes by Race/Ethnicity, Poverty, and State
B. Kohler (2015)
The estrogen receptor has a prognostic value in progesterone receptor-positive breast cancer
L. D. Maeyer (2006)
Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer.
C. Anders (2009)
Oncotype DX® Recurrence Score as a Predictor of Response to Neoadjuvant Chemotherapy
Alison M. Pease (2018)
National Comprehensive Cancer Network Breast Cancer (version 3.2020)
Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME II)
I H Kunkler (2015)
Oncotype DX Ò recurrence score as a predictor of response to neoadjuvant chemotherapy
A M Pease (2019)
Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study.
L. Carey (2006)
Subtypes of breast cancer show preferential site of relapse.
M. Smid (2008)
Outcomes of Estrogen Receptor Negative and Progesterone Receptor Positive Breast Cancer
M. Chan (2015)
Does estrogen receptor negative/progesterone receptor positive breast carcinoma exist?
Leen De Maeyer (2008)
Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer
S. Bae (2015)
Clinicopathological characteristics and breast cancer-specific survival of patients with single hormone-receptor breast cancer
Y Li (2020)
Single HR-Positive Breast Cancer Phenotype
Oncotype DX breast cancer recurrence score can be predicted with a novel nomogram using clinicopathologic data
Amila Orucevic (2017)
Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343.
Kevin S. Hughes (2013)
The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.
E. von Elm (2007)
Characterization of estrogen receptor-negative/progesterone receptor-positive breast cancer.
T. Shen (2015)

This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar